Navigation Links
Hayes, Inc. Technology Prognosis Team Tracks First-of-a-Kind Technologies
Date:5/7/2010

Healthcare professionals informed of every milestone leading to regulatory approval for Alair® and Provenge®

Lansdale, PA (PRWEB) -- Hayes Inc., the nation’s leading independent health technology research and consulting company, announces the release of two reports on first-of-a-kind technologies just approved by the Food and Drug Administration (FDA)—the Alair® Bronchial Thermoplasty System for medically refractory asthma, and the Provenge® prostate cancer vaccine for men with metastatic hormone-refractory disease. Hayes’ horizon scanning experts identified these emerging technologies more than 7 years ago as potential new options to address unmet treatment needs. Technology Prognosis, Hayes’ continuously updated horizon scanning service, has kept clients informed of every milestone leading to regulatory approval.

The Alair system for bronchial thermoplasty has potential to improve symptom control in adults with severe, medically refractory asthma, but the device and procedure have been evaluated in relatively few patients. The FDA based its approval on data from a clinical trial of 297 patients with severe and persistent asthma. The trial showed a reduction of severe asthma attacks with use of the Alair system. The FDA is requiring a 5-year postmarket study of the device to research its long-term safety and effectiveness.

Provenge is a vaccine given intravenously for the treatment of metastatic androgen-independent prostate cancer (AIPC), a grave condition with few treatment options. It does not prevent prostate cancer, and it is being evaluated only in patients already diagnosed with this disease. The vaccine appears to offer a modest but significant overall survival benefit in this patient subset but does not significantly delay the progression of the disease. Access to the vaccine may be limited initially by manufacturing capacity, as well as by cost concerns and issues of efficacy.

The Hayes Prognosis reports provide healthcare professionals with objective and unbiased information regarding these technologies, based on current evidence and expert analysis. The content includes the proposed clinical applications; relevant epidemiology and background information; an overview of anticipated costs, dissemination, and clinical setting requirements.

In addition, Hayes horizon scanning analysts offer conclusions and forecasts for anticipated adoption of these technologies. These insights provide hospitals, health insurers, and clinicians with guidance on appropriate technology applications, including patient selection and usage relative to existing clinical practice.

To learn more about Hayes Technology Prognosis, as well as purchase access to the Alair System and Provenge reports, contact us.

About Hayes, Inc.
Hayes, Inc. is an independent health technology research and consulting company dedicated to promoting better health outcomes through the use of evidence. Hayes performs unbiased, evidence-based healthcare technology assessments of the safety and efficacy of new, emerging, and controversial health technologies and evaluates the impact of these technologies on healthcare quality, utilization, and cost. Hayes’ worldwide clients include hospitals, healthcare systems, government agencies, employers, and managed care organizations. For more information, please visit www.hayesinc.com.

Contact:
Karen Matthias
215.855.0615

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb3974124.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Agricultural Biotechnology Addresses Consumer Demands for Healthier Foods
2. Innovative Technology Developed at AGH Accurately Monitors Healthcare Professionals' Handwashing Practices, Study Shows
3. Preventing blindness focus of ORNL technology, AMDx
4. Over 450 Patients Now Toenail Fungus Free Thanks to Your Next Step's New Toenail Fungus Laser Treatment Technology
5. Survey: Hiding risks can hurt public support for nanotechnology
6. Ross Nanotechnology Corporation Introduces the NeverWet™ Coating on its First Consumer Product – The Clear-n-Clean Plunger
7. "IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do
8. Korea Technology & Communications Joins HDcctv Alliance To Manufacture HDcctv-Compliant Cameras
9. PivotPoint Technology Launches Advanced SysML Training Services
10. Alterian Releases Professional Edition of its Content Manager Technology, Offering Partners and Clients an Even Faster Time-to-Live for Their Websites
11. In Coeur d'Alene Idaho, Top Of The Line Aesthetic Treatments And Non-Invasive Laser Technology Can Be Found Only At Advanced Aesthetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: